Emerging studies on retatrutide, a dual stimulant for incretin hormone and glucose-dependent insulinotropic polypeptide, indicate promising outcomes in addressing obesity and type 2 glucose intolerance. Early evidence from clinical assessments show notable decreases in body weight and improved glucose regulation. Ongoing exploration is focused on l